Mirati Therapeutics, Inc. (NASDAQ:MRTX) has been assigned an average rating of “Hold” from the nine brokerages that are presently covering the firm. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.07.

MRTX has been the subject of a number of research analyst reports. HC Wainwright set a $10.00 target price on Mirati Therapeutics and gave the company a “buy” rating in a research note on Saturday, March 11th. Zacks Investment Research raised Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research note on Wednesday, May 3rd. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $5.50 target price on shares of Mirati Therapeutics in a research note on Wednesday, April 12th.

Hedge funds and other institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. purchased a new position in Mirati Therapeutics during the first quarter valued at $106,000. Teachers Advisors LLC boosted its position in Mirati Therapeutics by 22.9% in the first quarter. Teachers Advisors LLC now owns 23,097 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 4,311 shares in the last quarter. Trexquant Investment LP boosted its position in Mirati Therapeutics by 21.1% in the fourth quarter. Trexquant Investment LP now owns 26,432 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 4,599 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 11,753 shares in the last quarter. Finally, Omega Advisors Inc. purchased a new position in Mirati Therapeutics during the first quarter valued at $520,000. 50.41% of the stock is owned by institutional investors.

WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/05/19/mirati-therapeutics-inc-mrtx-given-average-recommendation-of-hold-by-brokerages.html.

Shares of Mirati Therapeutics (NASDAQ:MRTX) opened at 3.60 on Friday. The stock’s market capitalization is $89.78 million. Mirati Therapeutics has a 52 week low of $3.10 and a 52 week high of $19.25. The company has a 50-day moving average price of $4.31 and a 200 day moving average price of $5.17.

Mirati Therapeutics (NASDAQ:MRTX) last posted its earnings results on Thursday, March 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.02. Analysts forecast that Mirati Therapeutics will post ($3.31) earnings per share for the current fiscal year.

Mirati Therapeutics Company Profile

5 Day Chart for NASDAQ:MRTX

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.